Showing results (81-90 of 102) with videos related to
Sort By:
Pageof 11
Nature Methods|August 21, 2007
Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detectionBrock A Peters, Zhengyan Kan, Dragan Sebisanovic, et al.Arthritis Care & Research|July 28, 2015
Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus ErythematosusRina Mina, Khalid Abulaban, Marisa S Klein-Gitelman, et al.The Journal of Rheumatology|April 3, 2020
Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry StudyKuan Liu, George Tomlinson, Ann M Reed, et al.Pigment Cell & Melanoma Research|March 18, 2014
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanomaWilliam R Jeck, Joel Parker, Craig C Carson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancerRoy S Herbst, Angela M Davies, Ronald B Natale, et al.BMC Medicine|November 16, 2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaborationLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.Nature Communications|September 21, 2021
The relevance of rock shape over mass-implications for rockfall hazard assessmentsAndrin Caviezel, Adrian Ringenbach, Sophia E Demmel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard, Bruce E Johnson, Lukas C Amler, et al.Pageof 11